A Study of Lasmiditan in Participants With Migraine
Status:
Completed
Trial end date:
2018-01-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to measure how much of the drug gets into the blood stream and
how long it takes the body to get rid of it during an acute migraine attack and also during
the time between acute migraine attacks.
Information about any side effects that may occur will also be collected.
This study includes two study periods. Each study period requires an overnight stay in the
Clinical Research Unit (CRU) for at least one night (and up to three nights), followed by up
to two outpatient appointments. This study will last approximately 5-6 weeks (not including
screening).
Follow-up is required four to seven days after last dose of investigational drug. Screening
is required within 28 days prior to the start of the study.
This study is for research purposes only and is not intended to treat any medical condition.